NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Although oncogene-targeted therapy often elicits profound initial tumor responses in patients, responses are generally incomplete because some tumor cells survive initial therapy as residual disease that enables eventual acquired resistance. The mechanisms underlying tumor cell adaptation and surviv...

Full description

Bibliographic Details
Main Authors: Collin M. Blakely, Evangelos Pazarentzos, Victor Olivas, Saurabh Asthana, Jenny Jiacheng Yan, Irena Tan, Gorjan Hrustanovic, Elton Chan, Luping Lin, Dana S. Neel, William Newton, Kathryn L. Bobb, Timothy R. Fouts, Jeffrey Meshulam, Matthew A. Gubens, David M. Jablons, Jeffrey R. Johnson, Sourav Bandyopadhyay, Nevan J. Krogan, Trever G. Bivona
Format: Article
Language:English
Published: Elsevier 2015-04-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S221112471500265X

Internet

http://www.sciencedirect.com/science/article/pii/S221112471500265X

Similar Items